Abstract

In recent years, there have been numerous breakthroughs in the fast expanding field of structure-based medication design. Numerous novel targets and chances for the development of therapeutic leads have been made possible by the explosion of genomic, proteomic, and structural information. This article provides an overview of the structure-based drug design process, focusing largely on the selection of a target, assessment of the target's
structural characteristics, key considerations to think about when selecting a method for drug lead discovery, and assessment of the drug leads. An analysis of drug design for AmpC -lactamase will serve as an example of key concepts in the field of structure-based drug design.